UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY

Home

Download

Statistics

Examples

Help

Contact

	Kinase Fusion Gene Summary
	Kinase Fusion Gene Sample Information
	Kinase Fusion ORF Analysis
	Kinase Fusion Amino Acid Sequences
	Multiple Sequence Alignment of All Fusion Protein Isoforms
	Kinase Fusion Protein Functional Features
	Kinase Fusion Protein Structures
	Comparison of Fusion Protein Isoforms
	Comparison of Fusion Protein Sequences/Structures with Known Sequences/Structures from PDB
	pLDDT Scores and Difference Analysis of pLDDT Scores Between the Active Sites (Best) and Non-Active Sites.
	Ramachandran Plot of Kinase Fusion Protein Structure
	Potential Active Site Information
	Virtual Screening Results
	Kinase-Substrate Information
	Related Drugs with This Kinase Fusion Protein
	Related Disease with This Kinase Fusion Protein
	Clinical Trials of the Found Drugs/Small Molecules

Kinase Fusion Gene:CREB3L3_PKN3

Kinase Fusion Protein Summary

Kinase Fusion gene summary

Kinase Fusion partner gene information	Kinase Fusion gene name: CREB3L3_PKN3
	KinaseFusionDB ID: KFG1430
	FusionGDB2.0 ID: KFG1430
		Hgene	Tgene
	Gene symbol	CREB3L3	PKN3
	Gene ID	84699	29941
	Gene name	cAMP responsive element binding protein 3 like 3	protein kinase N3
	Synonyms	CREB-H\|CREBH\|HYST1481\|HYTG2	UTDP4-1
	Cytomap	19p13.3	9q34.11
	Type of gene	protein-coding	protein-coding
	Description	cyclic AMP-responsive element-binding protein 3-like protein 3CREB/ATF family transcription factorcAMP-responsive element-binding protein, hepatic-specific	serine/threonine-protein kinase N3protein kinase PKN-betaprotein-kinase C-related kinase 3
	Modification date	20240305	20240305
	UniProtAcc	Q68CJ9	Q6P5Z2
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000078445, ENST00000595923, ENST00000602147, ENST00000602257, ENST00000252587,	ENST00000485301, ENST00000291906,
Context (manual curation of fusion genes in KinaseFusionDB)	PubMed: CREB3L3 [Title/Abstract] AND PKN3 [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	CREB3L3(4171172)-PKN3(131467582), # samples:3

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	CREB3L3	GO:0034976	response to endoplasmic reticulum stress	16469704
Hgene	CREB3L3	GO:0045944	positive regulation of transcription by RNA polymerase II	16469704
Tgene	PKN3	GO:0010631	epithelial cell migration	21754995

Kinase Fusion gene breakpoints across CREB3L3 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Kinase Fusion gene breakpoints across PKN3 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Kinase Fusion Gene Sample Information

Kinase Fusion gene information.

Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Sample	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp
ChimerDB4	TCGA-G3-A7M7-01A	CREB3L3	chr19	4171172	PKN3	chr9	131467582

Top

Kinase Fusion ORF Analysis

Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB.

Henst	Tenst	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Seq length (transcript)	Seq length (amino acids)
ENST00000078445	ENST00000291906	CREB3L3	chr19	4171172	PKN3	chr9	131467582	4080	1230

Top

Kinase Fusion Amino Acid Sequences

For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq

>ENST00000078445_ENST00000291906_CREB3L3_chr19_4171172_PKN3_chr9_131467582_length(amino acids)=1230
MAVGGPPAWSRDPPRHLQTELDGPMNTDLAAGKMASAACSMDPIDSFELLDLLFDRQDGILRHVELGEGWGHVKDQQVLPNPDSDDFLSS
ILGSGDSLPSSPLWSPEGSDSGISEDLPSDPQDTPPRSGPATSPAGCHPAQPGKGPCLSYHPGNSCSTTTPGPVIQVPEASVTIDLEMWS
PGGRICAEKPADPVDLSPRCNLTVKDLLLSGSSGDLQQHHLGASYLLRPGAGHCQELVLTEDEKKLLAKEGITLPTQLPLTKYEERVLKK
IRRKIRNKQSAQESRKKKKEYIDGLETRMSACTAQNQELQRKVLHLEKQNLSLLEQLKKLQAIVVQSTSKSAQTGTCVAPGPSQWPPEDE
KEVIRRAIQKELKIKEGVENLRRVATDRRHLGHVQQLLRSSNRRLEQLHGELRELHARILLPGPGPGPAEPVASGPRPWAEQLRARHLEA
LRRQLHVELKVKQGAENMTHTCASGTPKERKLLAAAQQMLRDSQLKVALLRMKISSLEASGSPEPGPELLAEELQHRLHVEAAVAEGAKN
VVKLLSSRRTQDRKALAEAQAQLQESSQKLDLLRLALEQLLEQLPPAHPLRSRVTRELRAAVPGYPQPSGTPVKPTALTGTLQVRLLGCE
QLLTAVPGRSPAAALASSPSEGWLRTKAKHQRGRGELASEVLAVLKVDNRVVGQTGWGQVAEQSWDQTFVIPLERARELEIGVHWRDWRQ
LCGVAFLRLEDFLDNACHQLSLSLVPQGLLFAQVTFCDPVIERRPRLQRQERIFSKRRGQDFLRASQMNLGMAAWGRLVMNLLPPCSSPS
TISPPKGCPRTPTTLREASDPATPSNFLPKKTPLGEEMTPPPKPPRLYLPQEPTSEETPRTKRPHMEPRTRRGPSPPASPTRKPPRLQDF
RCLAVLGRGHFGKVLLVQFKGTGKYYAIKALKKQEVLSRDEIESLYCEKRILEAVGCTGHPFLLSLLACFQTSSHACFVTEFVPGGDLMM
QIHEDVFPEPQARFYVACVVLGLQFLHEKKIIYRDLKLDNLLLDAQGFLKIADFGLCKEGIGFGDRTSTFCGTPEFLAPEVLTQEAYTRA
VDWWGLGVLLYEMLVGECPFPGDTEEEVFDCIVNMDAPYPGFLSVQGLEFIQKLLQKCPEKRLGAGEQDAEEIKVQPFFRTTNWQALLAR

--------------------------------------------------------------

Multiple Sequence Alignment of All Fusion Protein Isoforms

Top

Kinase Fusion Protein Functional Features

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:4171172/chr9:131467582)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
CREB3L3 Q68CJ9	PKN3 Q6P5Z2
FUNCTION: Transcription factor that may act during endoplasmic reticulum stress by activating unfolded protein response target genes. Activated in response to cAMP stimulation. In vitro, binds to the cAMP response element (CRE) and box-B element. Activates transcription through box-B element. Activates transcription through CRE (By similarity). May function synergistically with ATF6. In acute inflammatory response, may activate expression of acute phase response (APR) genes. May be involved in growth suppression. Regulates FGF21 transcription (By similarity). Plays a crucial role in the regulation of triglyceride metabolism and is required for the maintenance of normal plasma triglyceride concentrations (PubMed:21666694). {ECO:0000250, ECO:0000250\|UniProtKB:Q91XE9, ECO:0000269\|PubMed:11353085, ECO:0000269\|PubMed:15800215, ECO:0000269\|PubMed:16469704, ECO:0000269\|PubMed:21666694}.	FUNCTION: Contributes to invasiveness in malignant prostate cancer. {ECO:0000269\|PubMed:15282551}.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page
* Minus value of BPloci means that the break pointn is located before the CDS.

- Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt).

Partner

Hgeneene

Hbp

Tgeneene

Tbp

ENST

BPexon

TotalExon

Protein feature loci

BPloci

TotalLen

Feature

Note

- Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt).

Partner

Hgeneene

Hbp

Tgeneene

Tbp

ENST

BPexon

TotalExon

Protein feature loci

BPloci

TotalLen

Feature

Note

Tgene

CREB3L3

4171172

PKN3

131467582

ENST00000078445

819_889

890

Domain

Note=AGC-kinase C-terminal;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00618

Tgene

CREB3L3

4171172

PKN3

131467582

ENST00000078445

559_818

890

Domain

Note=Protein kinase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00159

Tgene

CREB3L3

4171172

PKN3

131467582

ENST00000078445

5_80

890

Domain

Note=REM-1 1;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU01207

Tgene

CREB3L3

4171172

PKN3

131467582

ENST00000078445

93_163

890

Domain

Note=REM-1 2;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU01207

Tgene

CREB3L3

4171172

PKN3

131467582

ENST00000078445

165_245

890

Domain

Note=REM-1 3;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU01207

Top

Kinase Fusion Protein Structures

CIF files of the predicted kinase fusion proteins
* Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format.

Kinase Fusion protein CIF link (fusion AA seq ID in KinaseFusionDB)	Henst	Tenst	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	AA seq	Len(AA seq)
PDB file >>>126_CREB3L3_PKN3	ENST00000078445	ENST00000291906	CREB3L3	chr19	4171172	PKN3	chr9	131467582	MAVGGPPAWSRDPPRHLQTELDGPMNTDLAAGKMASAACSMDPIDSFELLDLLFDRQDGILRHVELGEGWGHVKDQQVLPNPDSDDFLSS ILGSGDSLPSSPLWSPEGSDSGISEDLPSDPQDTPPRSGPATSPAGCHPAQPGKGPCLSYHPGNSCSTTTPGPVIQVPEASVTIDLEMWS PGGRICAEKPADPVDLSPRCNLTVKDLLLSGSSGDLQQHHLGASYLLRPGAGHCQELVLTEDEKKLLAKEGITLPTQLPLTKYEERVLKK IRRKIRNKQSAQESRKKKKEYIDGLETRMSACTAQNQELQRKVLHLEKQNLSLLEQLKKLQAIVVQSTSKSAQTGTCVAPGPSQWPPEDE KEVIRRAIQKELKIKEGVENLRRVATDRRHLGHVQQLLRSSNRRLEQLHGELRELHARILLPGPGPGPAEPVASGPRPWAEQLRARHLEA LRRQLHVELKVKQGAENMTHTCASGTPKERKLLAAAQQMLRDSQLKVALLRMKISSLEASGSPEPGPELLAEELQHRLHVEAAVAEGAKN VVKLLSSRRTQDRKALAEAQAQLQESSQKLDLLRLALEQLLEQLPPAHPLRSRVTRELRAAVPGYPQPSGTPVKPTALTGTLQVRLLGCE QLLTAVPGRSPAAALASSPSEGWLRTKAKHQRGRGELASEVLAVLKVDNRVVGQTGWGQVAEQSWDQTFVIPLERARELEIGVHWRDWRQ LCGVAFLRLEDFLDNACHQLSLSLVPQGLLFAQVTFCDPVIERRPRLQRQERIFSKRRGQDFLRASQMNLGMAAWGRLVMNLLPPCSSPS TISPPKGCPRTPTTLREASDPATPSNFLPKKTPLGEEMTPPPKPPRLYLPQEPTSEETPRTKRPHMEPRTRRGPSPPASPTRKPPRLQDF RCLAVLGRGHFGKVLLVQFKGTGKYYAIKALKKQEVLSRDEIESLYCEKRILEAVGCTGHPFLLSLLACFQTSSHACFVTEFVPGGDLMM QIHEDVFPEPQARFYVACVVLGLQFLHEKKIIYRDLKLDNLLLDAQGFLKIADFGLCKEGIGFGDRTSTFCGTPEFLAPEVLTQEAYTRA VDWWGLGVLLYEMLVGECPFPGDTEEEVFDCIVNMDAPYPGFLSVQGLEFIQKLLQKCPEKRLGAGEQDAEEIKVQPFFRTTNWQALLAR	1230
3D view using mol* of 126_CREB3L3_PKN3

PDB file >>>TKFP_207_CREB3L3_PKN3	ENST00000078445	ENST00000291906	CREB3L3	chr19	4171172	PKN3	chr9	131467582	MAVGGPPAWSRDPPRHLQTELDGPMNTDLAAGKMASAACSMDPIDSFELLDLLFDRQDGILRHVELGEGWGHVKDQQVLPNPDSDDFLSS ILGSGDSLPSSPLWSPEGSDSGISEDLPSDPQDTPPRSGPATSPAGCHPAQPGKGPCLSYHPGNSCSTTTPGPVIQVPEASVTIDLEMWS PGGRICAEKPADPVDLSPRCNLTVKDLLLSGSSGDLQQHHLGASYLLRPGAGHCQELVLTEDEKKLLAKEGITLPTQLPLTKYEERVLKK IRRKIRNKQSAQESRKKKKEYIDGLETRMSACTAQNQELQRKVLHLEKQNLSLLEQLKKLQAIVVQSTSKSAQTGTCVAPGPSQWPPEDE KEVIRRAIQKELKIKEGVENLRRVATDRRHLGHVQQLLRSSNRRLEQLHGELRELHARILLPGPGPGPAEPVASGPRPWAEQLRARHLEA LRRQLHVELKVKQGAENMTHTCASGTPKERKLLAAAQQMLRDSQLKVALLRMKISSLEASGSPEPGPELLAEELQHRLHVEAAVAEGAKN VVKLLSSRRTQDRKALAEAQAQLQESSQKLDLLRLALEQLLEQLPPAHPLRSRVTRELRAAVPGYPQPSGTPVKPTALTGTLQVRLLGCE QLLTAVPGRSPAAALASSPSEGWLRTKAKHQRGRGELASEVLAVLKVDNRVVGQTGWGQVAEQSWDQTFVIPLERARELEIGVHWRDWRQ LCGVAFLRLEDFLDNACHQLSLSLVPQGLLFAQVTFCDPVIERRPRLQRQERIFSKRRGQDFLRASQMNLGMAAWGRLVMNLLPPCSSPS TISPPKGCPRTPTTLREASDPATPSNFLPKKTPLGEEMTPPPKPPRLYLPQEPTSEETPRTKRPHMEPRTRRGPSPPASPTRKPPRLQDF RCLAVLGRGHFGKVLLVQFKGTGKYYAIKALKKQEVLSRDEIESLYCEKRILEAVGCTGHPFLLSLLACFQTSSHACFVTEFVPGGDLMM QIHEDVFPEPQARFYVACVVLGLQFLHEKKIIYRDLKLDNLLLDAQGFLKIADFGLCKEGIGFGDRTSTFCGTPEFLAPEVLTQEAYTRA VDWWGLGVLLYEMLVGECPFPGDTEEEVFDCIVNMDAPYPGFLSVQGLEFIQKLLQKCPEKRLGAGEQDAEEIKVQPFFRTTNWQALLAR	1230_CREB3L3_PKN3

Top

Comparison of Fusion Protein Isoforms

Superimpose the 3D Structures Among All Fusion Protein Isoforms
* Download the pdb file and open it from the molstar online viewer.

Comparison of the Secondary Structures of Fusion Protein Isoforms

Top

Comparison of Fusion Protein Sequences/Structures with Known Sequences/Structures from PDB

CREB3L3_PKN3 does not have any known PDB structures.

Top

pLDDT score distribution

all_data/KinaseFusionDB_T_Results/KinaseFusionDB_T_ViolinPlots/126_CREB3L3_PKN3.png

pLDDT score distribution of the predicted fusion protein structures from AlphaFold2
* AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100.
* The blue color at the bottom marks the best active site residues.

126_CREB3L3_PKN3.png

Top

Potential Active Site Information

The potential binding sites of these fusion proteins were identified using SiteMap, a module of the Schrodinger suite.

Kinase Fusion AA seq ID in KinaseFusionDB

Site score

Size

Dscore

Volume

Exposure

Enclosure

Contact

Phobic

Philic

Balance

Don/Acc

Residues

Top

Ramachandran Plot of Kinase Fusion Protein Structure

Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this fusion protein peptide.

126_CREB3L3_PKN3_ramachandran.png

Top

Virtual Screening Results

Distribution of the average docking score across all approved kinase inhibitors.
Distribution of the number of occurrence across all approved kinase inhibitors.

5'-kinase fusion protein case

3'-kinase fusion protein case

Top

Drug information from DrugBank of the top 20 interacting small molecules.
* The detailed information of individual kinase inhibitors are available in the download page.

Fusion gene name info	Drug	Docking score	Glide g score	Glide energy
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Lapatinib	-8.124839999999999	-8.21364	-67.4272
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Gilteritinib	-7.599760000000001	-7.6261600000000005	-50.1624
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Gilteritinib	-7.599760000000001	-7.6261600000000005	-50.1624
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Neratinib	-7.48567	-7.67157	-58.8837
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Neratinib	-7.261080000000001	-7.44338	-57.7467
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Neratinib	-7.261080000000001	-7.44338	-57.7467
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Neratinib	-7.129060000000001	-7.314960000000001	-54.6282
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Neratinib	-7.040660000000001	-7.2229600000000005	-54.0408
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Neratinib	-7.040660000000001	-7.2229600000000005	-54.0408
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Erdafitinib	-6.84002	-6.8402199999999995	-53.7194
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Lapatinib	-6.7595	-6.8483	-62.6231
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Lapatinib	-6.6714899999999995	-7.83989	-62.3201
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Lapatinib	-6.6714899999999995	-7.83989	-62.3201
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Cobimetinib	-6.389819999999999	-6.39262	-45.5278
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Ponatinib	-6.36776	-6.57436	-42.4936
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Ponatinib	-6.36776	-6.57436	-42.4936
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Ponatinib	-6.36776	-6.57436	-42.4936
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Lenvatinib	-6.19605	-6.19605	-46.3713
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Cabozantinib	-6.08829	-6.133290000000001	-42.7376
126_CREB3L3_PKN3-DOCK_HTVS_1-001	Cabozantinib	-6.08829	-6.133290000000001	-42.7376

Top

Kinase-Substrate Information of CREB3L3_PKN3

Phosphorylation target of the kinase
(phosphosite, 03-17-2024)

Kinase	Kinase UniProt Acc	Kinase species	Substrate	Substrate UniProt Acc	Substrate phosphorylated residues	Substrate phosphorylated sites (+/-7AA)	Domain
PKN3	Q6P5Z2	human	EGFR	P00533	T678	RHIVRKRtLRRLLQE
PKN3	Q6P5Z2	human	CLIP1	P30622	S312	AsLKRsPsAssLsSM

Biological Network Integration of This Kinase and Substrates
(GeneMANIA website)

Enriched GO biological processes of the phosphorylation target genes of the kinase

Kinase	GOID	GO term	P.adjust
PKN3	ID	Description	0.00e+00
PKN3	GO:0010749	regulation of nitric oxide mediated signal transduction	3.00e-02
PKN3	GO:0061029	eyelid development in camera-type eye	3.00e-02
PKN3	GO:0070141	response to UV-A	3.00e-02
PKN3	GO:1905208	negative regulation of cardiocyte differentiation	3.00e-02
PKN3	GO:0045737	positive regulation of cyclin-dependent protein serine/threonine kinase activity	3.00e-02
PKN3	GO:0038083	peptidyl-tyrosine autophosphorylation	3.00e-02
PKN3	GO:0038128	ERBB2 signaling pathway	3.00e-02
PKN3	GO:1904031	positive regulation of cyclin-dependent protein kinase activity	3.00e-02
PKN3	GO:0060571	morphogenesis of an epithelial fold	3.00e-02
PKN3	GO:0042059	negative regulation of epidermal growth factor receptor signaling pathway	3.00e-02
PKN3	GO:0007202	activation of phospholipase C activity	3.00e-02
PKN3	GO:0007263	nitric oxide mediated signal transduction	3.00e-02
PKN3	GO:0050999	regulation of nitric-oxide synthase activity	3.00e-02
PKN3	GO:0007435	salivary gland morphogenesis	3.00e-02
PKN3	GO:0031116	positive regulation of microtubule polymerization	3.00e-02
PKN3	GO:1901185	negative regulation of ERBB signaling pathway	3.00e-02
PKN3	GO:1905207	regulation of cardiocyte differentiation	3.00e-02
PKN3	GO:0007431	salivary gland development	3.00e-02
PKN3	GO:0031112	positive regulation of microtubule polymerization or depolymerization	3.00e-02
PKN3	GO:0010863	positive regulation of phospholipase C activity	3.00e-02
PKN3	GO:0071276	cellular response to cadmium ion	3.00e-02
PKN3	GO:0045740	positive regulation of DNA replication	3.00e-02
PKN3	GO:0071392	cellular response to estradiol stimulus	3.00e-02
PKN3	GO:1900274	regulation of phospholipase C activity	3.00e-02
PKN3	GO:0071364	cellular response to epidermal growth factor stimulus	3.00e-02
PKN3	GO:0032768	regulation of monooxygenase activity	3.00e-02
PKN3	GO:0035272	exocrine system development	3.00e-02
PKN3	GO:0070849	response to epidermal growth factor	3.00e-02
PKN3	GO:0021795	cerebral cortex cell migration	3.00e-02
PKN3	GO:0010518	positive regulation of phospholipase activity	3.00e-02
PKN3	GO:0048546	digestive tract morphogenesis	3.00e-02
PKN3	GO:1900087	positive regulation of G1/S transition of mitotic cell cycle	3.00e-02
PKN3	GO:1902895	positive regulation of miRNA transcription	3.00e-02
PKN3	GO:0048146	positive regulation of fibroblast proliferation	3.00e-02
PKN3	GO:0010517	regulation of phospholipase activity	3.00e-02
PKN3	GO:0031122	cytoplasmic microtubule organization	3.00e-02
PKN3	GO:0046686	response to cadmium ion	3.00e-02
PKN3	GO:0060193	positive regulation of lipase activity	3.00e-02
PKN3	GO:0022029	telencephalon cell migration	3.00e-02
PKN3	GO:0031113	regulation of microtubule polymerization	3.00e-02
PKN3	GO:1903078	positive regulation of protein localization to plasma membrane	3.00e-02
PKN3	GO:0042058	regulation of epidermal growth factor receptor signaling pathway	3.00e-02
PKN3	GO:0021885	forebrain cell migration	3.00e-02
PKN3	GO:2000630	positive regulation of miRNA metabolic process	3.00e-02
PKN3	GO:1902808	positive regulation of cell cycle G1/S phase transition	3.00e-02
PKN3	GO:1901224	positive regulation of non-canonical NF-kappaB signal transduction	3.00e-02
PKN3	GO:1901184	regulation of ERBB signaling pathway	3.00e-02
PKN3	GO:1902893	regulation of miRNA transcription	3.00e-02
PKN3	GO:0061614	miRNA transcription	3.00e-02

Top

Related Drugs to CREB3L3_PKN3

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Distribution of the number of studies mentioning CREB3L3-PKN3 and kinase inhibitors the PubMed Abstract (04-01-2024)

Fusion gene - drug pair 1

Fusion gene - drug pair 2

PMID

Publication date

DOI

Study title

Top

Related Diseases to CREB3L3_PKN3

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Related diseases from the literature mentioned this fusion gene and drug.
(PubMed, 04-01-2024)

MeSH ID

MeSH term

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

Top

Clinical Trials of the Found Drugs/Small Molecules

Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024)

Clinical Trials from clinicaltrials.gov (06-17-2024)

Fusion Gene

Kinase Inhibitor

NCT ID

Study Status

Phases

Disease

# Enrolment

Date